Early Empiric Anti-Mycobacterium Tuberculosis Therapy for Sepsis in Sub-Saharan Africa

Conditions:   Tuberculosis;   HIV I Infection;   Sepsis Interventions:   Other: Immediate anti-TB therapy;   Other: Sepsis-specific dose anti-TB therapy Sponsors:   University of Virginia;   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

AbstractUltraviolet blood irradiation (UBI) was used with success in the 1930s and 1940s for a variety of diseases. Despite the success, the lack of understanding of the detailed mechanisms of actions, and the achievements of antibiotics, phased off the use of UBI from the 1950s. The emergence of novel viral infections, from HIV/AIDS to Ebola, from SARS and MERS, and SARS-CoV-2, bring back the attention to this therapeutical opportunity. UBI has a complex virucidal activity, mostly acting on the immune system response. It has effects on lymphocytes (T-cells and B-cells), macrophages, monocytes, dendritic cells, low-density...
Source: Clinical Reviews in Allergy and Immunology - Category: Allergy & Immunology Source Type: research
CONCLUSION Compared with AlereLAM, FujiLAM detected 5 times more patients with TB in HIV-negative participants, had a high positive predictive value, and has the potential to improve rapid diagnosis of TB at the point-of-care. EclLAM demonstrated that additional sensitivity gains are possible, which highlights LAM’s potential as a biomarker. Additional research is required to assess FujiLAM’s performance in prospective cohorts, its cost-effectiveness, and its impact in real-world clinical settings.FUNDING Global Health Innovative Technology Fund, the UK Department for International Development, the Dutch Minist...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
AbstractObjectives: The Bacille Calmette-Gu érin (BCG) vaccine against tuberculosis is associated with non- specific protective effects against other infections, and significant reductions in all-cause morbidity and mortality have been reported. We aim to test whether BCG vaccination may reduce susceptibility to and/or the severity of COVID- 19 and other infectious diseases in health care workers (HCW) and thus prevent work absenteeism.The primary objective is to reduce absenteeism due to illness among HCW during the COVID-19 pandemic. The secondary objectives are to reduce the number of HCW that are infected with S...
Source: Trials - Category: Research Source Type: clinical trials
Abstract Infection is the predominant cause of mortality in early life, and immunization is the most promising biomedical intervention to reduce this burden. However, very young infants fail to respond optimally to most vaccines currently in use, especially neonates. In 2005, Stanley Plotkin proposed that new delivery systems would spur a new revolution in pediatric vaccinology, just as attenuation, inactivation, cell culture of viruses, genetic engineering, and adjuvantation had done in preceding decades. Recent advances in the field of immunoengineering, which is evolving alongside vaccinology, have begun to inc...
Source: Pediatric Research - Category: Pediatrics Authors: Tags: Pediatr Res Source Type: research
Conditions:   Mycobacterium Tuberculosis;   LTBI (Latent TB Infection);   Malnutrition;   Diabetes Mellitus;   Helminth Infections Intervention:   Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Mycobacterium Tuberculosis;   LTBI (Latent TB Infection);   Malnutrition;   Diabetes Mellitus;   Helminth Infections Intervention:   Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Mycobacterium Tuberculosis;   LTBI (Latent TB Infection);   Malnutrition;   Diabetes Mellitus;   Helminth Infections Intervention:   Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Mycobacterium Tuberculosis;   LTBI (Latent TB Infection);   Malnutrition;   Diabetes Mellitus;   Helminth Infections Intervention:   Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   HIV Infections;   Tuberculosis Interventions:   Drug: Bictegravir (BIC);   Drug: Tenofovir alafenamide (TAF);   Drug: Cabotegravir (CAB);   Drug: Dolutegravir (DTG);   Drug: Atazanavir/ritonavir (ATV/r);   Drug: Darunavir/ritonavir (DRV/r);   Drug: Lopinavir/ritonavir (LPV/r);   Drug: Cobicistat;   Drug: Ritonavir;   Drug: First-Line TB Treatment;   Drug: Second-Line TB Treatment;   Drug: Doravirine (DOR) Sponsor...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: African Health | Allergy | Allergy & Immunology | Infectious Diseases | Research | Tuberculosis